- Home
- PLRZ vs SLXN Comparison
PLRZ vs SLXN Comparison
Compare PLRZ & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRZ
- SLXN
- Stock Information
- Founded
- PLRZ 2005
- SLXN 2008
- Country
- PLRZ Israel
- SLXN Israel
- Employees
- PLRZ N/A
- SLXN N/A
- Industry
- PLRZ
- SLXN
- Sector
- PLRZ
- SLXN
- Exchange
- PLRZ NYSE
- SLXN NYSE
- Market Cap
- PLRZ 3.4M
- SLXN 3.0M
- IPO Year
- PLRZ 2024
- SLXN N/A
- Fundamental
- Price
- PLRZ $0.81
- SLXN $0.21
- Analyst Decision
- PLRZ
- SLXN Strong Buy
- Analyst Count
- PLRZ 0
- SLXN 1
- Target Price
- PLRZ N/A
- SLXN $1.00
- AVG Volume (30 Days)
- PLRZ 639.1K
- SLXN 1.5M
- Earning Date
- PLRZ 11-25-2024
- SLXN 11-14-2024
- Dividend Yield
- PLRZ N/A
- SLXN N/A
- EPS Growth
- PLRZ N/A
- SLXN N/A
- EPS
- PLRZ N/A
- SLXN N/A
- Revenue
- PLRZ N/A
- SLXN N/A
- Revenue This Year
- PLRZ N/A
- SLXN N/A
- Revenue Next Year
- PLRZ N/A
- SLXN N/A
- P/E Ratio
- PLRZ N/A
- SLXN N/A
- Revenue Growth
- PLRZ N/A
- SLXN N/A
- 52 Week Low
- PLRZ $0.77
- SLXN $0.21
- 52 Week High
- PLRZ $1.97
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- PLRZ N/A
- SLXN N/A
- Support Level
- PLRZ N/A
- SLXN N/A
- Resistance Level
- PLRZ N/A
- SLXN N/A
- Average True Range (ATR)
- PLRZ 0.00
- SLXN 0.00
- MACD
- PLRZ 0.00
- SLXN 0.00
- Stochastic Oscillator
- PLRZ 0.00
- SLXN 0.00
About PLRZ POLYRIZON LTD
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.